GLUC..2.88 Glucose Health Surpassed 2020 Sales At Amazon Manufactured by Glucose health Glucodown is the first and only healthy beverage brand to successfully reformulate popular soft drinks such as ice tea mixes and soon enhanced water drink mixes into diabetic friendly functional beverages.
LIVX..4.63 LiveXLive Incrases Guidance for 2022 Revenue to Between 107-115 million LivX is a Premium Internet Networks devoted to live music and music-related video content TipRanks Moderate Buy Target Price 7.00
Things Could Be Looking Up For this Penny ENZC...11 News this morning...Enzolytics Announced the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans to Commence Production Of Monoclonal Antibodies Targeting These Sites
Penny For Your Thoughts BTZI...072..Bots Announced this morning Acquired ATM Network..Launches Growth Strategy To Deploy Bitcoin ATMS Great Asset to Debt Ratio Assets 71 million Debt 500K In March reached .14..Feb .34
June Gem SESN..2.97..Sesen Bio Pharmaceutical Fusion protein tumor-targeting antibodies to cytotoxic proteins..Result is a single protein molecule that kills cancer cells. Drug Candidate Vicineum is for treatment of non-muscle invasive bladder cancer Grown faster 74% than US Industry average 17% Return on Equity forecast to be high in 4 years 1,310% Forecast to generate higher return on assets 65% than US Industry average of 11% Forecast To Grow 111% per year Analyst HC Wainwright gives it a Buy with Target Price 8.00 Barshart Strong Buy TipRanks Target Price 7.50
From Bear To Bull A TipRanks Recommendation RDHL..7.05 Redhill Bio-Pharm treats gastrointestinal issues.. Three drugs with approval Movantik treatment for opiod-induces constipation Talicia treatment for pylori infection Aemcolo treatment for diarrhea Gross profit 27.5 million 100 million cash on hand Return on Equity projected in four years to be 7,600% Return on Assets is 587% compared to US Industry averag 14% Revenue has grown 635% compared to Industry average of 17% Revenue forecast to grow 66% Analyst HC Wainwright Upgraded To Buy with Target Price 23.00 TipRanks Strong Buy Target Price 20.50
The Little Stock That Could Where will this be in one year? UCLE..54 Average Volume 45,000..Today 200,000 Low .50....did reach high of .60 Their Supercapacitors ability to charge batteries of EV's in minutes..
Up 75% after the Bell VTNR..3.12..Vertex Energy Just announced acquired Alabama Refinery Before Uptick Considered Undervalued Float 28 million StockTA Bullish Short Barchart Strong Buy TipRanks Moderate buy Target Price 3.00..Again pre purchase announcment
SBFM...1520..Dipped Down 37% Monday at .09..today high of .31 Yesterday rose on positive results from its cancer drug candidate
News Last Night CIAFF..5.24 Champion Iron Reported Record Financial Results Exploration and development of iron ore in Quebec, Canada Revenue 396 million First quarter 2021 ..Revenue 175 million First quarter 2020 Cash Flow 275 million compared to 175 million same time last year Market Cap 2.5 billion Vangurd holds 4.9 million shares worth 19.7 million dollars StockTA Very Bullish Long Barchart Strong Buy
Up 33% pre-market ZSAN..99 Announced positive results on their Drug Qtrypta a treatment for Acute Migraines TipRanks Moderate buy Target Price 2.25
News at 5 OCGN..7.66 Ocugen On Track To Submit US and EUA Application For Covaxin..Vaccine For Covid-19
With Volume Increase Could Be A Buy and Hold FRLN..9.15 Freeline Therapeutics Gene Therapies for debilitating chronic diseases including bleeding disorders Four Drugs In Development Pipeline Two For Hemophilia One for Fabry Disease One For Gaucher Disease Low float 12 million TipRanks Strong Buy Target price 24.50
HNRC..1.79..Targets over $6.00 per share Houston Natural Resources confirmed currently has a total of $9.67 per share in assets Company's net asset value $4.71 per share for period ending March 31 ,2021 Company's subsidiary Houston Natural Resources has appraised vlue of $69 million in proven reserves valued at $4.47 per share HNRI has 2800 acres of oil and gas leases located in Texas
Watch List Big Insider Buying This Week...$2,000,000 worth of shares ESPR..19.97..Esperian Therapeutics Pharm developing and commercializing oral therapies for treatment of patients with elevated low-density lipoprotein cholesterol Low Float 26 million Return on Equity 230% Revenue has grown faster 27% than US Market average of 16% TipRanks Moderate Buy Target Price 59.71
UCLE..54 Highlighted on Investor Hub this morning US Nuclear's Grapheton glassy carbon super capicitor is positioning to become the needed breakthrough for ultra-fast charging electric vehicles
